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Abstract 
Previous studies demonstrated paired helical filament r (PHFr) in neuritic but not diffuse /?-amyloid (AB) plaques in Alzheimer’s disease (AD). 
Re-examination of amyloid deposits with antibodies to A/I and PHFr by conventional and confocal microscopy using double label immunohistochem- 
istry showed that PHFr is a component of both diffuse and neuritic plaques in AD. Unlike controls, a dense network of PHFr positive dystrophic 
neurites extended throughout he AD neocortex permeating nearly all neuritic and diffuse plaques. Thus, PHFz-rich dystrophic neurites are common 
components of neuritic and diffuse plaques in AD neocortex. 
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1. Introduction 
j?-Amyloid peptides (A/?) derived from one or more 
amyloid precursor proteins accumulate in plaques 
throughout the Alzheimer disease (AD) brain [1,2]. A/3 
is produced in the normal and AD brain, and it is se- 
creted by cultured cells including human neurons [3-6]. 
Although the mechanisms leading to the aggregation and 
fibrillogenesis of secreted A/I are unknown, amyloid pla- 
ques contain several components that have been impli- 
cated in the genesis of these lesions [7-141. However, two 
major types of 48 deposits, i.e. the neuritic and diffuse 
plaque, differ with respect to composition and structure 
[7,&l 1,12,14]. For example, aberrantly phosphorylated 
r proteins (A68 or PHFz) that form paired helical tila- 
ments (PHFs) in neurofibrillary tangles (NFTs) have 
been found in dystrophic processes associated with 
neuritic plaques (NPs), but a number of studies have 
failed to detect PHFr in diffuse plaques [14]. Since this 
might signify that diffuse and neuritic plaques arise from 
different mechanisms, we re-examined this issue by con- 
ventional and confocal microscopy using double label 
immunohistochemistry. 
To determine if PHFr is a common or inconstant 
component of different types of A@ deposits, we re-exam- 
ined the association of PHFr with w in NPs and diffuse 
plaques using several monoclonal (MAbs) and polyclo- 
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nal antibodies to defined epitopes in A/I, normal r and 
PHFr. A recently developed MAb (PHFl) to an aber- 
rantly phosphorylated epitope in PHFz [15-l 81, was in- 
cluded here because this MAb labeled a more extensive 
network of dystrophic neurites in the AD brain than 
other antibodies to normal fetal and adult r or PHFr (see 
below). Indeed, unlike other antibodies to normal r and 
PHFr, PHFl labeled PHFz-rich dystrophic neurites in 
nearly all of the A/3 deposits in AD neocortex including 
diffuse plaques. In contrast, few neuritic and diffuse pla- 
ques were labeled by PHFl in control neocortex. 
2. Materials and methods 
2.1. Tkxe collection 
Postmortem samples of neocortex obtained from 12 patients with 
AD ranging in age from 56 to 89 (average =77) and 4 elderly controls 
ranging in age from 71 to 91 (average = 81) without evidence of a 
neurological disease were used in this study. The average postmortem 
interval was 11 h for the AD patients and 12 h for the controls. The 
diagnosis of AD was based on consensus criteria [19] as described 
[7,11,12]. None of the AD cases had cortical Lewy bodies [14,20]. Five 
cortical areas were studied, i.e. superior temporal gyrus (area 22), 
midfrontal gyrus (area 9110) gyrus rectus (area 11), and occipital cortex 
(area 17). All tissue samples were immersion fixed in 70% ethanol with 
150 mM NaCl and embedded in paraffin as described [7,11,12]. 
2.2. Antibody probes 
The ability of PHFl to detect PHFr-rich NFTs and dystrophic 
neurites was compared with that of 11 other previously characterized 
antibodies pecific for normal r and/or PHFr (Alz50, T60, Tau2, T46, 
T14, T3P, 133, 304, 189, 135, 134) all of which label neurofibrillary 
lesions in situ [7,1 l-14,17,21-31]. Based on preliminary studies, three 
of these antibodies that most intensely labeled abundant NFTs and 
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dystrophic neurites were selected for detailed comparison with PHFl 
in the quantitative double label studies described here. These antibodies 
included: T14, an MAb that recognizes a phosphate-independent epi- 
tope within amino acids 141-178 [25] according to the numbering sys- 
tem for the 441 amino acid long r isofonn [31]; T46, an MAb to a 
phosphate independent epitope within amino acids 404441 [25], and 
T3P, a rabbit antiserum that binds to a phosphate dependent epitope 
within amino acids 389402 only when set-me-396 is phosphorylated 
[27]. The phosphate dependent r epitopes recognized by T3P and PHFl 
are nearly identical [17,18,27], and both epitopes are found in PHFr 
and normal fetal CNS r, but not in any of the six alternatively spliced 
isoforms of r found in the postmortem adult CNS [17,23,27]. To label 
deposits of w, polyclonal antisera to A/T4 (UP107) and A/7,_,2 (2332) 
were used [l l-131. Finally, a MAb (2.2BlO) to glial fibrillary acidic 
protein (GFAP; [32]) also was used to identify NPs in double stained 
preparations since reactive astrocytes infiltrate NPs but not diffuse 
plaques [ll-14,331. 
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2.3. Immunohistochemical procedures 
Immunohistochemistry was carried out with the peroxidase anti- 
peroxidase procedure for both single and double label studies 
[l l-l 3,341. Double labeling also involved immunohistochemistry fol- 
lowed by Thiotlavine S staining as described [12,34,35]. To retard 
Thioflavine S fading, the sections were mounted in medium containing 
0.25% p-phenylenediamine, 5%N-propyl gallate, and 0.0025% 1,4-di- 
azabicyclo-(2,2,2)-octane [35,36] and viewed with brightfield and fluo- 
rescent illumination. Additionally, selected alcohol fixed frozen and 
paraffin embedded sections were probed with antibodies using a Texas 
red and fluorescein isothiocyanate detection systems, and these sections 
were viewed with a conventional f uorescence microscope and a LEICA 
confocal microscope [14,20,35]. The positive and negative controls for 
these studies were as described [l l-13,20,22,25-27,29,32-35]. 
2.4. Quantitation of immunohistochemical results 
Areas of highest plaque density were selected for quantitative analy- 
Fig. 1. The color photomicrographs in panels A-D illustrate bright field (A and B), or confocal (C and D) images of A@ plaques double labeled with 
the anti-w antiserum 2332 (gray-blue reaction product in A and B; green fluorescence in C and D) in combination with either the anti-PHFr antibody 
PHFl (brown reaction product in A and B; red fluorescence in C) or with the anti-r antibody T46 (red fluorescence in D). Neocortical samples from 
2 different AD patients are shown in A, C and D while B shows neocortex from an elderly control subject. PHFl labeled dystrophic process (arrows) 
are more prominent in A and C than in B and D. Panels A and B are at the same magnification and the scale bar in A = 25 pm, while C and D 
are at the same magnification and the scale bar in C = 10 pm. In C and D, autofluorescent lipofuscin was edited out using Adobe Photoshop. 
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sis. Plaques within a one mm2 area of a cortical region were counted 
[7,11,12], and a Student’s t-test was used to assess the statistical signif- 
icance of differences between single and double labeled amyloid plaques 
in the AD and control brains. 
3.Redts 
Neocortical samples from all of the AD patients (Figs. 
lA,C,D and 2A-C) and three control cases (Figs. 1B and 
2A-C) contained amyloid plaques labeled by antibodies 
to A/9,_,,, (UP107) and A&,, (2332). As reported, [l, 1 l- 
14,331, anti+3 antibodies labeled many more plaques 
than Thioflavine S or other amyloid stains, and the num- 
ber of A/3 labeled plaques/mm’ was similar in some of the 
AD and control neocortical samples (Fig. 2A). In con- 
trast, a far greater number of @ plaques in the AD 
neocortex was associated with dystrophic neurites la- 
beled by the anti-z (T14, T46) and anti-PHFz (T3P, 
PHFl) antibodies (Fig. 2B,C). Indeed, no T14 positive 
plaques double labeled with anti-@ antibodies were 
seen in the controls, and a significantly greater number 
(P c 0.001) of plaques double labeled with the PHF-1 
MqS and the anti-A@ antibodies was found in the AD 
neocortex compared to control samples. NPs were read- 
ily distinguished from diffuse plaques in sections double 
labeled with antibodies to A/3 in conjunction with anti- 
bodies to normal adult z, PHFz and GFAP (data not 
shown). 
In contrast to other antibodies to normal CNS z or 
PHFz that label plaque associated dystrophic neurites 
[14], the PHFl MAb demonstrated immunoreactive lin- 
ear and punctate profiles throughout the AD neocortex 
and in nearly all diffuse plaques in the AD brains, but 
only a small number of PHFl positive dystrophic 
neurites were seen in control brains and diffuse plaques 
71 
in the controls rarely contained PHFl positive profiles 
(Fig. 1 and 2). Indeed, PHFl usually labeled dystrophic 
processes in > 2-3 times more A#? positive deposits than 
T14, T46 and T3P. This was due to the greater frequency 
with which PHFl labeled dystrophic neurites in the AD 
neocortex and in diffuse plaques (Fig. 2B,C). This find- 
ing is provocative because previous studies performed 
with a large number of other antibodies to a variety of 
epitopes distributed over large stretches of normal adult 
z or PHFr have failed to detect normal z or PHFz in 
diffuse plaques of the AD, control or Doti’s syndrome 
brain [1,7,11,12,14,33]. 
Additional immunohistochemical studies were con- 
ducted to determine if the ability of PHFl to detect 
PHFz-rich profiles in diffuse plaques reflected the exqui- 
site sensitivity and specificity of PHFl for PHFz-rich 
processes in situ. For example, T14, T46 and PHFl were 
used in parallel to probe adjacent sections of frontal 
cortex from control and AD brains. As described earlier 
[29], T14 and T46 stained axons in the normal cortical 
neuropil, but not the somato-dendritic domain of neu- 
rons, while normal adult neocortex was almost com- 
pletely negative when probed with PHFl. Further, T14 
and PHFl stained numerous NFTs and dystrophic 
neurites in AD neocortex, but PHFl labeled more 
PHFz-rich lesions than T14 (Figs. 2 and 3), and PHFl 
continued to label these lesions at much higher dilutions 
than T14 (data not shown). Detailed confocal analysis of 
serial optical sections at 1 firn intervals over a z-axis 
distance of 15 pm through the AD neocortex confirmed 
these findings (Fig. 3). Indeed, PHFl revealed a much 
denser meshwork of PHFz positive dystrophic neurites 
than T14, T46, T3P or any other anti-z or anti-PHFz 
antibody used in this or previous studies [7,1 l- 
14,20,22,25,27,33,35]. 
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Fig. 2. Histograms of the counts of single (A) and double (B and C) labeled plaques in a representative neocortical area (i.e. area 9/10) of the AD 
(cases 1-12) and control (cases 13-16) brains. The rabbit polyclonal antiserum to w (2332) was used alone to label diffuse and neuritic plaques in 
A, while 2332 was used in a double label procedure with the mouse MAbs T14 and PHFl in B and C. The absence of solid bars for some of the 
control cases in the histograms indicate that no single or double labeled plaques were identified. The scale for the vertical axis in all of the histograms 
is the same. The difference between the number of double labeled plaques in AD versus control cortical samples in C is statistically significant 
(P c 0.001). See text for further details on quantitative methods and interpretation of the results shown here. 
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Fig. 3. Confocal images of two adjacent 30 pm thick sections of AD 
neocortex (area 900) that were optically sectioned at 1 ,um intervals 
spanning a 15 pm thickness following immunofluorescent labeling of 
each section with PHFl (A) or T14 (B). The optical sections were 
superimposed and these representative fields demonstrate the greater 
abundance of the dystrophic neurites revealed by the PHFl MAb. The 
bar in A = 25 pm. 
4. Discussion 
We demonstrated that PHFr positive dystrophic 
neurites are present throughout the AD neocortex and 
in nearly all NPs and diffuse plaques in these regions. 
The more extensive network of PHFr positive processes 
revealed by PHFl probably reflects the greater affinity 
of this antibody for abnormally phosphorylated PHFr. 
Indeed, PHFl binds more avidly to synthetic r peptides 
phosphorylated on both SePg6 and Serm than to the 
same r peptides with phosphates on either Ser396 or Ser4@’ 
(unpublished). Notably, both Ser396 and Ser404 are abnor- 
mally phosphorylated in the AD brain compared to the 
normal postmortem brain [17,18,27]. While the relation- 
ship of neuritic and diffuse plaques to each other is not 
known, diffuse plaques may be precursor lesions of the 
more complex NPs that contain abundant A/I fibrils and 
other elements including dystrophic neurites, microglia 
and reactive astrocytes. Based on the data presented 
here, we conclude that PHFr is a constituent not only of 
NPs, but also of most diffuse plaques in the AD neo- 
cortex. In contrast, PHFr is infrequent in the amyloid 
deposits found in the control neocortex. 
Although the precise role of w in the pathogenesis of 
neuron loss and dementia in AD remains controversial 
[1,2,14], the demonstration that M is secreted into the 
cerebrospinal fluid of the normal and AD brain [4,5] 
suggests that plaque formation in AD may depend on 
extracellular ‘factors’ which favor the aggregation and 
polymerization of A/I into amyloid fibrils. Indeed, an 
understanding of how A/? contributes to neuron degener- 
ation in AD may await the characterization of factors in 
the extracellular space that promote the aggregation and 
fibrillogenesis of secreted A/3. Although some correlative 
and experimental evidence suggests that proteoglycans 
could play a role in the assembly of A/? into amyloid 
fibrils [9,37,38], other extracellular matrix proteins (e.g. 
laminin) also have been implicated in these events [39]. 
The demonstration that injections of PHFr into the ro- 
dent brain induce co-deposits of A+9 [13], and that A/I [40] 
and APP fragments associate with PHFr [41] provide 
evidence for interactions between A/?, amyloid precursor 
proteins and PHFr [ll-14,421 that could contribute to 
the formation of amyloid plaques. This notwithstanding, 
the evidence that soluble A/? is a normal metabolic prod- 
uct of neural cells should prompt further studies of the 
fate of secreted @ and the biological significance of the 
convergence of qS with other components in amyloid 
plaques. 
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